Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials
At ZenFit Wellness, patients are evaluated to determine if they qualify for treatment
pharmacy and dispensed only with a valid prescription
Before recommending semaglutide, tirzepatide, or another medically supervised weight-loss strategy, a physician may review weight history, prior weight-loss attempts, BMI, waist circumference, body composition goals, A1C, fasting glucose, insulin-resistance risk, cholesterol, triglycerides, blood pressure, liver enzymes, fatty liver risk, kidney function, current medications, diabetes medication use, history of pancreatitis, gallbladder disease, gastrointestinal symptoms, thyroid history, protein intake, exercise habits, sleep quality, hormonal symptoms, inflammation-related concerns, side-effect tolerance, and long-term maintenance planning
In SARMOUNT-5 trials, tirzepatide participants lost 20.2% of body weight, while semaglutide users showed a 13.7% reduction in body weight over 72 weeks